Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 12/20 | 0.55 |
| ▸ | CRBN | Q96SW2 | 12/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | IKZF2 | Q9UKS7 | 3/20 | 0.42 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | WNT3A | P56704 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22291602 | 0.94 | DDB1 (0.54) | DDB1CRBNKDM4EMAPTTHRB | |
| SCHEMBL24299447 | 0.86 | CRBN (0.55) | DDB1CRBNMAPT | |
| SCHEMBL20046321 | 0.84 | CRBN (0.58) | DDB1CRBN | |
| SCHEMBL29367285 | 0.84 | CRBN (0.58) | DDB1CRBN | |
| SCHEMBL24406575 | 0.83 | CRBN (0.47) | DDB1CRBNKDM4EMAPTTHRB | |
| SCHEMBL24481058 | 0.83 | CRBN (0.48) | DDB1CRBN | |
| SCHEMBL29583366 | 0.82 | IKZF2 (0.63) | DDB1CRBNIKZF2IKZF1 | |
| SCHEMBL20046085 | 0.82 | IKZF2 (0.63) | DDB1CRBNIKZF2IKZF1 | |
| SCHEMBL22291548 | 0.82 | CRBN (0.46) | DDB1CRBN | |
| SCHEMBL24299444 | 0.81 | CRBN (0.54) | DDB1CRBNMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12391686-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-20240150348-A1 | BRD9 DEGRADERS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-05-09 | — | — | US | disclosed |
| US-11787800-B2 | BRD9 degraders and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787800-B2 | BRD9 degraders and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787800-B2 | BRD9 degraders and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2023-10-17 | — | — | US | disclosed |
| EP-4188447-A1 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20230077730-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2023-03-16 | — | — | US | disclosed |
| US-20220048906-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2022-02-17 | — | — | US | disclosed |
| US-20220048906-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2022-02-17 | — | — | US | disclosed |
| WO-2022025880-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2022-02-03 | — | — | WO | disclosed |
| WO-2022025880-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2022-02-03 | — | — | WO | disclosed |
| CN-113874016-A | Compound and use thereof | 福宏治疗公司 | 2021-12-31 | — | — | CN | disclosed |
| EP-3917526-A1 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2021-12-08 | — | — | EP | disclosed |
| WO-2020160192-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2020-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220048906-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | DDB1 699/4885CRBN 56/4885KDM4E 1238/4885 |
| US-20230077730-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | DDB1 699/4885CRBN 56/4885KDM4E 1238/4885 |
| US-12391686-B2 | Compounds and uses thereof | VHL, TFEB, BECN1 | DDB1 699/4885CRBN 56/4885KDM4E 1238/4885 |
| US-20240150348-A1 | BRD9 DEGRADERS AND USES THEREOF | BRD9, BRWD1, BRD2 | DDB1 895/4885CRBN 60/4885KDM4E 855/4885 |
| US-11787800-B2 | BRD9 degraders and uses thereof | BRD9, BRWD1, BRD2 | DDB1 895/4885CRBN 60/4885KDM4E 855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.